Issue link: http://www.e-digitaleditions.com/i/751389
Tablets & Capsules November 2016 21 Differences Down-Under: Australian labels for complemen- tary medicines vs. US labels for dietary supplements. Robert Forbes. September 2010, p. 32D. Dispelling solid dosage misinterpretations of the USP-NF. Susan J. Schniepp. October 2009, p. 14. Drug product recalls: An overview of the process. Edward J. Bauer. May 2012, p. 8. Effect of sampling methods on vitamin D blending unifor- mity. Wenming Zeng, Dan Wang, and Doug Roper. October 2016, p. 17. Elemental impurities. John McCarty. Eye on Excipients, March 2013, p. 39. Elemental impurities limits. John A. McCarty. Eye on Excipients, May 2012, p. 33. Embracing QbD and PAT in nutraceutical production. Misty Muscarella, Charles Preuss, Y.V. Pathak, and Adnan Sabir. October 2011, p. 18. Excipient quality and QbD. Alen Guy. Eye on Excipients, January 2012, p. 39. Excipient selection: Practical advice on using SUPAC. Metin Çelik. July 2008, p. 15. Excipients in the news. Matthew Knopp. Back Page, July 2013, p. 48. FDA hones guidance on PCIDs. Peter M. O. Wong. Back Page, April 2012, p. 56. FDASIA's effect on excipients. Bretta Lichtenhan, Dale Carter, Megan Bevill, Katherine Ulman, and Julie Budnick. Eye on Excipients, October 2013, p. 39. GMP compliance: The top seven pitfalls. Greta Houlahan. January 2012, p. 32B. Have a plan before the FDA arrives. Bryan J. Coleman. Back Page, October 2016, p. 52. Hospital unit-dose blisters: New format comes with new challenges. Bob Hartwig. May 2013, p. 8. How to ensure your dust collection system complies with combustible-dust standards. David Steil, Tony Supine, and Mike Walters. May 2013, p. 20. IPEC regulatory affairs conference 2007. John A. McCarty. Eye on Excipients, January 2008, p. 52. IPEC regulatory affairs conference 2008. John A. McCarty. Eye on Excipients, October 2008, p. 61. IPEC regulatory affairs conference 2009. John A. McCarty. Eye on Excipients, January 2010, p. 31. Implementing cleaning validation requires process under- standing. Parveen Bhandola. October 2012, p. 8. Incorporating comprehensive serialization in the pharmaceu- tical industry. Andrew Pietrangelo. October 2016, p. 23. In-place cleaning and washing: Determining the need CIP and WIP systems for tablet presses. Stefania Barzanti, Caterina Funaro, Fabriano Ferrini, and Marcus Behrens. September 2010, p. 8. Ingredient identity testing: The road to GMP compliance. Mara Whitten. April 2011, p. 32C. Is tablet coating ready for QbD? Michael Choi. Back Page, April 2009, p. 48. Management responsibility for a serialization and aggrega- tion system. Marcus Pabsch. March 2014, p. 33. Measuring bulk density: Advantages of a shear cell. Vinnie Hebert. October 2013, p. 31. Measuring water activity as a means to reduce microbial limit testing. Anthony J. Fontana. October 2008, p. 28. NDI Draft Guidance: A year later. Jusin J. Prochnow. July 2012, p. 32C. Navigating the landscape of structure/function statements. Justin J. Prochnow. October 2011, p. 32C. New ADIs and GMPs spell C-H-A-N-G-E. Emily Nystrom. March 2008, p. 18. New developments in dissolution testing of tablets and cap- sules. Margareth R. C. Marques, William Brown, Gabriel Giancaspro, Natalia Davydova, Edith Chang, Jeanne Fringer, Walter Hauck, and Anthony DeStefano. October 2012, p. 12. The new dietary-supplement GMPs: An invitation to sci- ence. Barry Brown. September 2008, p. 32C. A new framework for using new excipients? Matthew Knopp. Eye on Excipients, January 2014, p. 39. New USP elemental impurity testing: Selecting a method. Andrew Fussell. Back Page, March 2015, p. 48. Options for conducting elemental impurities testing. Timothy Klock. Back Page, July 2016, p. 48. Pediatric formulations. Alen Guy. Eye on Excipients, April 2013, p. 37. The problem areas in meeting dietary-supplement cGMPs. Joy Joseph. October 2011, p. 26. QbD and co-processed excipients: A low-risk alternative to API-in-capsule for expediting first-in-human studies. Adam Lambert. March 2014, p. 18. A Quality-by-Design comparison of two film coating sys- tems. Brian Cheng. April 2013, p. 12. Quality by Design's impact on the cost of drug develop- ment. Ken Seufert. October 2013, p. 17. Recent challenges in dissolution testing, including USP ini- tiatives. Vivian A. Gray, January 2012, p. 28. Regulatory compliance: Patients talk. Ben Locwin. Back Page, October 2012, p. 48. Responses to the final GMP rule for dietary supplements. Emily Nystrom. October 2007, p. 29. The role of the ingredient supplier in cGMP compliance. Rupa Das. January 2009, p. 32C. The role of NIR spectroscopy in meeting the PAT chal- lenge. Frederick H. Long. March 2007, p. 20. Safety evaluations of new excipients. Christopher DeMerlis, Elaine V. Knight, R. Christian Moreton, and Robert E. Osterberg. Eye on Excipients, April 2011, p. 39. Stability modeling and package selection. Matthew Knopp. May 2016, p. 11. i n d e x t o a r t i c l e s